Table 1 Characteristics of the patient population subdivided by the polymorphisms in CYP2C19 and CYP2D6.
CYP2C19 EM | CYP2C19 IM + PM | P value | CYP2D6 UM + EM | CYP2D6 IM + PM | P value | |
|---|---|---|---|---|---|---|
Age | 55 (28-69) | 57 (31-66) | 0.80 | 56 (28-69) | 56 (35-68) | 0.5 |
β2-micro-globulin | 3.7 (1.2-55.6) | 4.9 (1.5-22.0) | 0.09 | 4.1 (1.3-36.0) | 3.7 (1.2-56.6) | 0.9 |
Creatinine | 1.1 (0.6-9.4) | 1.3 (0.5-8.4) | 0.03 | 1.1 (0.5-9.4) | 1.1 (0.7-6.9) | 0.8 |
Albumin | 3.5 (0.3-5.3) | 3.3 (1.6-5.3) | 0.07 | 3.5 (0.3-5.2) | 3.5 (0.3-5.0) | 0.5 |
Durie-Salmon Stage | ||||||
I | 29 (11%) | 5 (7%) | 0.4 | 10 (8%) | 11 (11%) | 0.5 |
II | 62 (24%) | 14 (19%) | 25 (20%) | 23 (23%) | ||
III | 167 (65%) | 54 (74%) | 89 (72%) | 64 (65%) | ||
ISS | ||||||
I | 46 (25%) | 8 (16%) | 0.04 | 18 (22%) | 21 (28%) | 0.5 |
II | 78 (42%) | 15 (31%) | 33 (41%) | 24 (32%) | ||
III | 60 (33%) | 26 (53%) | 30 (37%) | 29 (39%) | ||
Sex | ||||||
male | 149 (56%) | 48 (66%) | 0.2 | 68 (54%) | 68 (67%) | 0.04 |
female | 116 (44%) | 25 (34%) | 59 (46%) | 33 (33%) |